Kyprolis

(Carfilzomib)

Kyprolis

Drug updated on 11/9/2023

Dosage FormInjection (intravenous; 10 mg, 30 mg, 60 mg)
Drug ClassProteasome inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone.
  • Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with dexamethasone.
  • Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and dexamethasone.
  • Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and hyaluronidase-fihj and dexamethasone.
  • Indicated for use as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
  • Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Isatuximab and dexamethasone.

Product Monograph / Prescribing Information

Document TitleYearSource
Kyprolis (carfilzomib) Prescribing Information2022Onyx Pharmaceuticals, Inc., Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis. 2023Hematology
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis. 2023Hematologica
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: a network meta‚Äźanalysis of randomized clinical trials.2022Hematological Oncology
Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.2022Annals of Hematology
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis. 2022Hematology
Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis. 2022Medicine
A systematic review and network meta-analysis of randomized data on efficacy of novel therapy combinations in patients with lenalidomide-refractory multiple myeloma.2021Clinical Lymphoma, Myeloma and Leukemia
A systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma.2021Cancers
Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials.2020Annals of Hematology
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. 2020Blood
Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis.2018JAMA Oncology
Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: a systematic review.2018Critical Reviews in Oncology/Hematology
A comparison of the efficacy of immunomodulatory-containing regimens in relapsed/refractory multiple myeloma: a network meta-analysis.2018Clinical Lymphoma, Myeloma & Leukemia

Clinical Practice Guidelines